User profiles for ANWAAR SAEED
Anwaar SaeedUniversity of Pittsburgh Medical Center (UPMC) & UPMC Hillman Cancer Center Verified email at upmc.edu Cited by 1998 |
Total neoadjuvant therapy vs standard therapy in locally advanced rectal cancer: a systematic review and meta-analysis
Importance Standard therapy for locally advanced rectal cancer includes concurrent
chemoradiotherapy followed by surgery and adjuvant chemotherapy (CRT plus A). An alternative …
chemoradiotherapy followed by surgery and adjuvant chemotherapy (CRT plus A). An alternative …
[HTML][HTML] The integration of immune checkpoint inhibitors with VEGF targeted agents in advanced gastric and gastroesophageal adenocarcinoma: a review on the …
Several targeted therapies have shown efficacy in patients with advanced gastric cancer (GC)
and gastroesophageal junction adenocarcinoma (GEJC), including anti-angiogenic …
and gastroesophageal junction adenocarcinoma (GEJC), including anti-angiogenic …
[HTML][HTML] Similar response rates and survival with PARP inhibitors for patients with solid tumors harboring somatic versus Germline BRCA mutations: a Meta-analysis …
Background PARP inhibitors (PARPi) have recently been approved for various malignancies
based on the results of several clinical trials. However, these trials have mostly recruited …
based on the results of several clinical trials. However, these trials have mostly recruited …
Biologics, immunotherapy, and future directions in the treatment of advanced cholangiocarcinoma
Gemcitabine plus cisplatin remains the standard first-line systemic therapy for advanced
cholangiocarcinoma and offers a median survival of approximately 1 year. No standard …
cholangiocarcinoma and offers a median survival of approximately 1 year. No standard …
[HTML][HTML] Immuno-oncotherapeutic approaches in advanced hepatocellular carcinoma
Advanced hepatocellular carcinoma has limited treatment options, but there has been
extensive growth recently with cabozantinib, regorafenib, lenvatinib, nivolumab, atezolizumab, …
extensive growth recently with cabozantinib, regorafenib, lenvatinib, nivolumab, atezolizumab, …
Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child‐Pugh A and B cirrhosis: a real …
…, K Schulze, H Wege, VE Gaillard, A Saeed… - Hepatology, 2022 - journals.lww.com
Preliminary evidence of safety and tolerability of atezolizu... : Hepatology Preliminary
evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with …
evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with …
Immunotherapy and targeted therapy for advanced gastroesophageal cancer: ASCO guideline
…, A Nagarajan, H Park, A Saeed… - Journal of Clinical …, 2023 - ingentaconnect.com
PURPOSE To develop recommendations involving targeted therapies for patients with
advanced gastroesophageal cancer. METHODS The American Society of Clinical Oncology …
advanced gastroesophageal cancer. METHODS The American Society of Clinical Oncology …
T-cell exhaustion and residency dynamics inform clinical outcomes in hepatocellular carcinoma
…, T Berg, L Rimassa, L Di Tommaso, A Saeed… - Journal of …, 2022 - Elsevier
Background & Aims Despite recent translation of immunotherapies into clinical practice, the
immunobiology of hepatocellular carcinoma (HCC), in particular the role and clinical …
immunobiology of hepatocellular carcinoma (HCC), in particular the role and clinical …
Clinical outcomes and toxic effects of single-agent immune checkpoint inhibitors among patients aged 80 years or older with cancer: a multicenter international cohort …
Importance Geriatric (aged ≥80 years) patients are historically underrepresented in cancer
clinical trials. Little is known about the efficacy of immune checkpoint inhibitors (ICIs) in …
clinical trials. Little is known about the efficacy of immune checkpoint inhibitors (ICIs) in …
[HTML][HTML] Treatment-related toxicity and improved outcome from immunotherapy in hepatocellular cancer: evidence from an FDA pooled analysis of landmark clinical …
Purpose The development of treatment-related adverse events (trAE) correlates favorably
with clinical outcomes in multiple studies of patients receiving immune checkpoint inhibitors (…
with clinical outcomes in multiple studies of patients receiving immune checkpoint inhibitors (…